Cargando…
The OECD Program to Validate the Rat Hershberger Bioassay to Screen Compounds for in Vivo Androgen and Antiandrogen Responses. Phase 1: Use of a Potent Agonist and a Potent Antagonist to Test the Standardized Protocol
The Organisation for Economic Cooperation and Development (OECD) has completed phase 1 of the Hershberger validation intended to identify in vivo activity of suspected androgens and anti-androgens. Seventeen laboratories from 7 countries participated in phase 1, and results were collated and evaluat...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
National Institute of Environmental Health Sciences
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1552005/ https://www.ncbi.nlm.nih.gov/pubmed/16882536 http://dx.doi.org/10.1289/ehp.8751 |
_version_ | 1782129326958837760 |
---|---|
author | Owens, William Zeiger, Errol Walker, Michael Ashby, John Onyon, Lesley Gray, L. Earl |
author_facet | Owens, William Zeiger, Errol Walker, Michael Ashby, John Onyon, Lesley Gray, L. Earl |
author_sort | Owens, William |
collection | PubMed |
description | The Organisation for Economic Cooperation and Development (OECD) has completed phase 1 of the Hershberger validation intended to identify in vivo activity of suspected androgens and anti-androgens. Seventeen laboratories from 7 countries participated in phase 1, and results were collated and evaluated by the OECD with the support of an international committee of experts. Five androgen-responsive tissues (ventral prostate, paired seminal vesicles and coagulating glands, levator ani and bulbocavernosus muscles, glans penis, and paired Cowper’s or bulbourethral glands) were evaluated. The standardized protocols used selected doses of a reference androgen, testosterone propionate (TP), and an antiandrogen, flutamide (FLU). All laboratories successfully detected TP-stimulated increases in androgen-responsive tissue weight and decreases in TP-stimulated tissue weights when FLU was co-administered. The standardized protocols performed well under a variety of conditions (e.g., strain, diet, housing protocol, bedding). There was good agreement among laboratories with regard to the TP doses inducing significant increases in tissue weights and the FLU doses decreasing TP-stimulated tissue weights. Several additional procedures (e.g., weighing of the dorsolateral prostate and fixation of tissues before weighing) and serum component measurements (e.g., luteinizing hormone) were also included by some laboratories to assess their potential utility. The results indicated that the OECD Hershberger protocol was robust, reproducible, and transferable across laboratories. Based on this phase 1 validation study, the protocols have been refined, and the next phase of the OECD validation program will test the protocol with selected doses of weak androgen agonists, androgen antagonists, a 5α-reductase inhibitor, and chemicals having no androgenic activity. |
format | Text |
id | pubmed-1552005 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | National Institute of Environmental Health Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-15520052006-08-29 The OECD Program to Validate the Rat Hershberger Bioassay to Screen Compounds for in Vivo Androgen and Antiandrogen Responses. Phase 1: Use of a Potent Agonist and a Potent Antagonist to Test the Standardized Protocol Owens, William Zeiger, Errol Walker, Michael Ashby, John Onyon, Lesley Gray, L. Earl Environ Health Perspect Research The Organisation for Economic Cooperation and Development (OECD) has completed phase 1 of the Hershberger validation intended to identify in vivo activity of suspected androgens and anti-androgens. Seventeen laboratories from 7 countries participated in phase 1, and results were collated and evaluated by the OECD with the support of an international committee of experts. Five androgen-responsive tissues (ventral prostate, paired seminal vesicles and coagulating glands, levator ani and bulbocavernosus muscles, glans penis, and paired Cowper’s or bulbourethral glands) were evaluated. The standardized protocols used selected doses of a reference androgen, testosterone propionate (TP), and an antiandrogen, flutamide (FLU). All laboratories successfully detected TP-stimulated increases in androgen-responsive tissue weight and decreases in TP-stimulated tissue weights when FLU was co-administered. The standardized protocols performed well under a variety of conditions (e.g., strain, diet, housing protocol, bedding). There was good agreement among laboratories with regard to the TP doses inducing significant increases in tissue weights and the FLU doses decreasing TP-stimulated tissue weights. Several additional procedures (e.g., weighing of the dorsolateral prostate and fixation of tissues before weighing) and serum component measurements (e.g., luteinizing hormone) were also included by some laboratories to assess their potential utility. The results indicated that the OECD Hershberger protocol was robust, reproducible, and transferable across laboratories. Based on this phase 1 validation study, the protocols have been refined, and the next phase of the OECD validation program will test the protocol with selected doses of weak androgen agonists, androgen antagonists, a 5α-reductase inhibitor, and chemicals having no androgenic activity. National Institute of Environmental Health Sciences 2006-08 2006-02-27 /pmc/articles/PMC1552005/ /pubmed/16882536 http://dx.doi.org/10.1289/ehp.8751 Text en http://creativecommons.org/publicdomain/mark/1.0/ Publication of EHP lies in the public domain and is therefore without copyright. All text from EHP may be reprinted freely. Use of materials published in EHP should be acknowledged (for example, ?Reproduced with permission from Environmental Health Perspectives?); pertinent reference information should be provided for the article from which the material was reproduced. Articles from EHP, especially the News section, may contain photographs or illustrations copyrighted by other commercial organizations or individuals that may not be used without obtaining prior approval from the holder of the copyright. |
spellingShingle | Research Owens, William Zeiger, Errol Walker, Michael Ashby, John Onyon, Lesley Gray, L. Earl The OECD Program to Validate the Rat Hershberger Bioassay to Screen Compounds for in Vivo Androgen and Antiandrogen Responses. Phase 1: Use of a Potent Agonist and a Potent Antagonist to Test the Standardized Protocol |
title | The OECD Program to Validate the Rat Hershberger Bioassay to Screen Compounds
for in Vivo Androgen and Antiandrogen Responses. Phase 1: Use of a Potent Agonist
and a Potent Antagonist to Test the Standardized Protocol |
title_full | The OECD Program to Validate the Rat Hershberger Bioassay to Screen Compounds
for in Vivo Androgen and Antiandrogen Responses. Phase 1: Use of a Potent Agonist
and a Potent Antagonist to Test the Standardized Protocol |
title_fullStr | The OECD Program to Validate the Rat Hershberger Bioassay to Screen Compounds
for in Vivo Androgen and Antiandrogen Responses. Phase 1: Use of a Potent Agonist
and a Potent Antagonist to Test the Standardized Protocol |
title_full_unstemmed | The OECD Program to Validate the Rat Hershberger Bioassay to Screen Compounds
for in Vivo Androgen and Antiandrogen Responses. Phase 1: Use of a Potent Agonist
and a Potent Antagonist to Test the Standardized Protocol |
title_short | The OECD Program to Validate the Rat Hershberger Bioassay to Screen Compounds
for in Vivo Androgen and Antiandrogen Responses. Phase 1: Use of a Potent Agonist
and a Potent Antagonist to Test the Standardized Protocol |
title_sort | oecd program to validate the rat hershberger bioassay to screen compounds
for in vivo androgen and antiandrogen responses. phase 1: use of a potent agonist
and a potent antagonist to test the standardized protocol |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1552005/ https://www.ncbi.nlm.nih.gov/pubmed/16882536 http://dx.doi.org/10.1289/ehp.8751 |
work_keys_str_mv | AT owenswilliam theoecdprogramtovalidatetherathershbergerbioassaytoscreencompoundsforinvivoandrogenandantiandrogenresponsesphase1useofapotentagonistandapotentantagonisttotestthestandardizedprotocol AT zeigererrol theoecdprogramtovalidatetherathershbergerbioassaytoscreencompoundsforinvivoandrogenandantiandrogenresponsesphase1useofapotentagonistandapotentantagonisttotestthestandardizedprotocol AT walkermichael theoecdprogramtovalidatetherathershbergerbioassaytoscreencompoundsforinvivoandrogenandantiandrogenresponsesphase1useofapotentagonistandapotentantagonisttotestthestandardizedprotocol AT ashbyjohn theoecdprogramtovalidatetherathershbergerbioassaytoscreencompoundsforinvivoandrogenandantiandrogenresponsesphase1useofapotentagonistandapotentantagonisttotestthestandardizedprotocol AT onyonlesley theoecdprogramtovalidatetherathershbergerbioassaytoscreencompoundsforinvivoandrogenandantiandrogenresponsesphase1useofapotentagonistandapotentantagonisttotestthestandardizedprotocol AT graylearl theoecdprogramtovalidatetherathershbergerbioassaytoscreencompoundsforinvivoandrogenandantiandrogenresponsesphase1useofapotentagonistandapotentantagonisttotestthestandardizedprotocol AT owenswilliam oecdprogramtovalidatetherathershbergerbioassaytoscreencompoundsforinvivoandrogenandantiandrogenresponsesphase1useofapotentagonistandapotentantagonisttotestthestandardizedprotocol AT zeigererrol oecdprogramtovalidatetherathershbergerbioassaytoscreencompoundsforinvivoandrogenandantiandrogenresponsesphase1useofapotentagonistandapotentantagonisttotestthestandardizedprotocol AT walkermichael oecdprogramtovalidatetherathershbergerbioassaytoscreencompoundsforinvivoandrogenandantiandrogenresponsesphase1useofapotentagonistandapotentantagonisttotestthestandardizedprotocol AT ashbyjohn oecdprogramtovalidatetherathershbergerbioassaytoscreencompoundsforinvivoandrogenandantiandrogenresponsesphase1useofapotentagonistandapotentantagonisttotestthestandardizedprotocol AT onyonlesley oecdprogramtovalidatetherathershbergerbioassaytoscreencompoundsforinvivoandrogenandantiandrogenresponsesphase1useofapotentagonistandapotentantagonisttotestthestandardizedprotocol AT graylearl oecdprogramtovalidatetherathershbergerbioassaytoscreencompoundsforinvivoandrogenandantiandrogenresponsesphase1useofapotentagonistandapotentantagonisttotestthestandardizedprotocol |